Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]
Shiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.On page 1029, the first sentence of the introduction section reads as “C...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-10-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | https://www.dovepress.com/erratum-profile-of-tezacaftorivacaftor-combination-and-its-potent-peer-reviewed-article-TCRM |
| Summary: | Shiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.On page 1029, the first sentence of the introduction section reads as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately ct 380,000 people worldwide.1” This should read as “Cystic fibrosis (CF) is a life-threatening genetic disease that affects approximately 80,000 people worldwide.1”Read the original article |
|---|---|
| ISSN: | 1178-203X |